Orlando, FL 3/7/12 (StreetBeat) -- On Tuesday, Intellect Neurosciences (PK: ILNS), the little-known penny stock biopharmaceutical company with enormous stakes in the race for the treatment of Alzheimer's, announced that it had received important news from the United States Patent and Trademark Office.The firm secured patent claims covering their own ANTISENILIN® monoclonal antibody platform technology for the treatment and prevention of Alzheimer's disease and this news is certainly expected to affect their bottom line and valuation -- especially since the low priced, fully reporting company has royalty-bearing licenses with multiple Big Pharma partners who are leading the way in an effort to solve the Alzheimer's puzzle.
As noted in a Barron's article last week, scientists at those giant pharmaceutical firms may have a better idea by the third quarter of this year of whether two drugs can help the world's 26 million Alzheimer's victims.
Barron's looked at the prospects for the pharmaceutical companies that are developing these potentially life-changing treatments and while they did not mention ILNS by name, that small biotech has substantial interests and involvement in the development of those drug candidates and their pending clinical trial results.
Whether the evidence from the current late stage trials is positive or not, industry observers expect to see the "bio trader's run up" effect in anticipation of that important clinical data's release. That effect from speculators taking positions in the stocks will be critical to the success of the New York-based firm whose shares have been starting to rebound following a toxic financing which saw its market cap almost completely destroyed in 2010.
What has saved Intellect has been the promise of its science, its growing patent portfolio and its potentially lucrative licensing agreements.
Dr. Daniel Chain -- who discovered much of the science being used by Big Pharma and formed Intellect in April 2005 -- currently serves as the Chairman and Chief Executive Officer at Intellect Neurosciences. In an interview with BioMedReports, he explains some of the details and relevant information related to the patent news released this morning.
StreetBeat Disclaimer
No comments:
Post a Comment